{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:08:10Z","timestamp":1791443290428,"version":"4.3.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Discov"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.<\/jats:p>","DOI":"10.1038\/s41421-021-00320-y","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T13:05:20Z","timestamp":1631019920000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates"],"prefix":"10.1038","volume":"7","author":[{"given":"Xiaoyan","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-6127","authenticated-orcid":false,"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijuan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhong","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiliang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenJuan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizu","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3234-9616","authenticated-orcid":false,"given":"Zhiming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-3782","authenticated-orcid":false,"given":"Chao","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengfu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"320_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","volume":"21","author":"L Dai","year":"2021","unstructured":"Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"320_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","volume":"397","author":"OJ Wouters","year":"2021","unstructured":"Wouters, O. J. et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet 397, 1023\u20131034 (2021).","journal-title":"Lancet"},{"key":"320_CR3","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"324","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA 324, 951\u2013960 (2020).","journal-title":"JAMA"},{"key":"320_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect. Dis. 21, 39\u201351 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"320_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 803\u2013812 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"320_CR6","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"320_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"320_CR8","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993 (2021).","journal-title":"Lancet"},{"key":"320_CR9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"320_CR10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","volume":"182","author":"L Dai","year":"2020","unstructured":"Dai, L. et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722\u2013733 (2020).","journal-title":"Cell"},{"key":"320_CR11","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"320_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1126\/science.abf6097","volume":"371","author":"P Zhou","year":"2021","unstructured":"Zhou, P. & Shi, Z. L. SARS-CoV-2 spillover events. Science 371, 120\u2013122 (2021).","journal-title":"Science"},{"key":"320_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"320_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu, B., Guo, H., Zhou, P. & Shi, Z. L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141\u2013154 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"320_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RD Jiang","year":"2020","unstructured":"Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358 (2020).","journal-title":"Cell"},{"key":"320_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41422-020-0364-z","volume":"30","author":"C Shan","year":"2020","unstructured":"Shan, C. et al. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques. Cell Res. 30, 670\u2013677 (2020).","journal-title":"Cell Res."},{"key":"320_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan, J. et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581, 215\u2013220 (2020).","journal-title":"Nature"},{"key":"320_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"W Tai","year":"2020","unstructured":"Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol. Immunol. 17, 613\u2013620 (2020).","journal-title":"Cell Mol. Immunol."},{"key":"320_CR19","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","volume":"586","author":"J Yang","year":"2020","unstructured":"Yang, J. et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature 586, 572\u2013577 (2020).","journal-title":"Nature"},{"key":"320_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20653-8","volume":"12","author":"JH Tian","year":"2021","unstructured":"Tian, J. H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).","journal-title":"Nat. Commun."},{"key":"320_CR21","doi-asserted-by":"publisher","first-page":"104868","DOI":"10.1016\/j.antiviral.2020.104868","volume":"182","author":"X Pan","year":"2020","unstructured":"Pan, X. et al. Immunoglobulin fragment F(ab\u2019)2 against RBD potently neutralizes SARS-CoV-2 in vitro. Antivir. Res. 182, 104868 (2020).","journal-title":"Antivir. Res."},{"key":"320_CR22","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","volume":"182","author":"J Sun","year":"2020","unstructured":"Sun, J. et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment. Cell 182, 734\u2013743 (2020).","journal-title":"Cell"},{"key":"320_CR23","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372\u20132383 (2021).","journal-title":"Cell"},{"key":"320_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-020-00402-5","volume":"5","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target Ther. 5, 282 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"320_CR25","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv https:\/\/doi.org\/10.1101\/2021.03.08.434499 (2021).","DOI":"10.1101\/2021.03.08.434499"},{"key":"320_CR26","doi-asserted-by":"publisher","first-page":"E1059","DOI":"10.1503\/cmaj.1095949","volume":"193","author":"D Duong","year":"2021","unstructured":"Duong, D. Alpha, Beta, Delta, Gamma: What\u2019s important to know about SARS-CoV-2 variants of concern? CMAJ 193, E1059\u2013E1060 (2021).","journal-title":"CMAJ"},{"key":"320_CR27","doi-asserted-by":"publisher","first-page":"108630","DOI":"10.1016\/j.celrep.2020.108630","volume":"34","author":"SM Gobeil","year":"2021","unstructured":"Gobeil, S. M. et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1\/S2 junction. Cell Rep. 34, 108630 (2021).","journal-title":"Cell Rep."},{"key":"320_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19808-4","volume":"11","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 11, 6013 (2020).","journal-title":"Nat. Commun."},{"key":"320_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-020-2895-3","volume":"592","author":"JA Plante","year":"2021","unstructured":"Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116\u2013121 (2021).","journal-title":"Nature"},{"key":"320_CR30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1126\/science.abe8499","volume":"370","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science 370, 1464\u20131468 (2020).","journal-title":"Science"},{"key":"320_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2020.09.032","volume":"183","author":"L Yurkovetskiy","year":"2020","unstructured":"Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell 183, 739\u2013751 (2020).","journal-title":"Cell"},{"key":"320_CR32","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477\u2013488 e474 (2021).","journal-title":"Cell Host Microbe"},{"key":"320_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41392-021-00536-0","volume":"6","author":"C Li","year":"2021","unstructured":"Li, C. et al. The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct. Target Ther. 6, 132 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"320_CR34","doi-asserted-by":"publisher","unstructured":"Huang, B. et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv https:\/\/doi.org\/10.1101\/2021.02.01.429069 (2021).","DOI":"10.1101\/2021.02.01.429069"},{"key":"320_CR35","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","volume":"27","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717\u2013726 (2021).","journal-title":"Nat. Med."},{"key":"320_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","volume":"27","author":"X Xie","year":"2021","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. 27, 620\u2013621 (2021).","journal-title":"Nat. Med."},{"key":"320_CR37","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1056\/NEJMc2102017","volume":"384","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. N. Engl. J. Med. 384, 1466\u20131468 (2021).","journal-title":"N. Engl. J. Med."},{"key":"320_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMc2106083","volume":"385","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N. Engl. J. Med. 385, 472\u2013474 (2021).","journal-title":"N. Engl. J. Med."},{"key":"320_CR39","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1016\/j.cell.2021.06.020","volume":"184","author":"C Liu","year":"2021","unstructured":"Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220\u20134236.e13 (2021).","journal-title":"Cell"},{"key":"320_CR40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"320_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","volume":"596","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature 596, 273\u2013275 (2021).","journal-title":"Nature"},{"key":"320_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat. Med. 27, 270\u2013278 (2021).","journal-title":"Nat. Med."},{"key":"320_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","volume":"183","author":"AO Hassan","year":"2020","unstructured":"Hassan, A. O. et al. A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2. Cell 183, 169\u2013184.e113 (2020).","journal-title":"Cell"},{"key":"320_CR44","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.chom.2021.06.001","volume":"29","author":"A Tauzin","year":"2021","unstructured":"Tauzin, A. et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe 29, 1137\u20131150.e1136 (2021).","journal-title":"Cell Host Microbe"},{"key":"320_CR45","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881\u2013891 (2021).","journal-title":"Lancet"},{"key":"320_CR46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637\u2013646 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"320_CR47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682\u2013694 (2021).","journal-title":"Lancet"},{"key":"320_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107\u20131119 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"320_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/science.abg8663","volume":"372","author":"CM Saad-Roy","year":"2021","unstructured":"Saad-Roy, C. M. et al. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. Science 372, 363\u2013370 (2021).","journal-title":"Science"}],"container-title":["Cell Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41421-021-00320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-021-00320-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41421-021-00320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T05:11:27Z","timestamp":1669957887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41421-021-00320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1038\/s41421-021-00320-y","relation":{},"ISSN":["2056-5968"],"issn-type":[{"value":"2056-5968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors J.S., L.Z., C.G., H.Z., Y.D.L., Z.L.W., X.L.H., W.J.C., L.J.F., Y.X.Y., J.Z., H.X., J.Z.Y., and P.F.Z. are current or past employees of Wuhan YZY Biopharma Co., Ltd, a for-profit organization, and these authors own stock or hold stock options. These interests do not alter the authors adherence to policies on sharing data and materials. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"82"}}